Browse > Article
http://dx.doi.org/10.7314/APJCP.2016.17.4.2185

Sensitive and Noninvasive Detection of Aberrant SFRP2 and MGMT-B Methylation in Iranian Patients with Colon Polyps  

Naini, M Alizade (Department of Internal Medicine, School of Medicine, Shiraz University of Medical Sciences)
Mokarram, P (Gastroenterohepatology Research Center, Nemazi Hospital, School of Medicine, Shiraz University of Medical Sciences)
Kavousipour, S (Biotechnology, School of Advanced Medical Science and Technologies, Shiraz University of Medical Sciences)
Zare, N (Department of Biochemistry, Science and Research Branch, Islamic Azad University)
Atapour, A (Biotechnology, School of Advanced Medical Science and Technologies, Shiraz University of Medical Sciences)
Zarin, M Hassan (Department of Internal Medicine, School of Medicine, Shiraz University of Medical Sciences)
Mehrabani, G (School of Medicine, Shiraz University of Medical Sciences)
Borji, M (Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.4, 2016 , pp. 2185-2193 More about this Journal
Abstract
Background: The pathogenesis of sporadic colorectal cancer (CRC) is influenced by the patient genetic background and environmental factors. Based on prior understanding, these are classified in two major pathways of genetic instability. Microsatellite instability (MSI) and CPG island methylator phenotype (CIMP) are categorized as features of the hypermethylated prototype, and chromosomal instability (CIN) is known to be indicative of the non-hypermethylated category. Secreted frizzled related protein 2 (SFRP2), APC1A in WNT signaling pathway and the DNA repair gene, O6-methylguanine-DNA methyltransferase (MGMT), are frequently hypermethylated in colorectal cancer. Detection of methylated DNA as a biomarker by easy and inexpensive methods might improve the quality of life of patients with CRC via early detection of cancer or a precancerous condition. Aim: To evaluate the rate of SFRP2 and MGMT hypermethylation in both polyp tissue and serum of patients in south Iran as compared with matched control normal population corresponding samples. Materials and Methods: Methylation-specific PCR was used to detect hypermethylation in DNA extracted from 48 polypoid tissue samples and 25 healthy individuals. Results: Of total polyp samples, 89.5% had at least one promoter gene hypermethylation. The most frequent methylated locus was SFRP2 followed by MGMT-B (81.2 and 66.6 percent respectively). Serologic detection of hypermethylation was 95% sensitive as compared with polyp tissue. No hypermethylation was detected in normal tissue and serum and its detection in patients with polyps, especially of serrated type, was specific. Conclusions: Serologic investigation for detection of MGMT-B, SFRP2 hypermethylation could facilitate prioritization of high risk patients for colonoscopic polyp detection and excision.
Keywords
Colorectal cancer; polyp; MGMT; SFRP2; APC; methylation; serum diagnosis;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Bishehsari F, Mahdavinia M, Vacca M, et al (2014). Epidemiological transition of colorectal cancer in developing countries: Environmental factors, molecular pathways, and opportunities for prevention. World J Gastroenterol, 20, 6055-72.   DOI
2 Carethers JM, Jung BH (2015). Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. Gastroenterol, 149, 1177- 90.e3.   DOI
3 Chang E, Park DI, Kim YJ, et al (2010). Detection of colorectal neoplasm using promoter methylation of ITGA4, SFRP2, and p16 in stool samples: a preliminary report in Korean patients. Hepatogastroenterol, 57, 720-7.
4 Coppede F, Lopomo A, Spisni R, et al (2014). Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer. World J Gastroenterol, 20, 943-56.   DOI
5 De Maio G, Rengucci C, Zoli W, et al (2014). Circulating and stool nucleic acid analysis for colorectal cancer diagnosis. World J Gastroenterol, 20, 957-67.   DOI
6 Esteller M, Hamilton SR, Burger PC, et al (1999). Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res, 59, 793-7.
7 Feldman M, Friedman LS (2010). Sleisenger and Fordtran's Gastrointestinal and Liver Disease. In Eds Saunders elsevier. Philadelphia.
8 Fisher JA, Fikry C, Troxel AB (2006). Cutting cost and increasing access to colorectal cancer screening: another approach to following the guidelines. Cancer Epidemiol Biomarkers Prev, 15, 108-13.   DOI
9 Hagrass HA, Pasha HF, Shaheen MA, et al (2014). Methylation status and protein expression of RASSF1A in breast cancer patients. Mol Biol Rep, 41, 57-65.   DOI
10 Halford S, Rowan A, Sawyer E, et al (2005). O(6)-methylguanine methyltransferase in colorectal cancers: detection of mutations, loss of expression, and weak association with G:C>A:T transitions. Gut, 54, 797-802.   DOI
11 Hassanzade J, Molavi EVH, Farahmand M, et al (2011). Incidence and mortality rate of common gastrointestinal cancers in south of Iran, a population based study. Iran J Cancer Prev, 4, 163-9.
12 Heitzer E, Ulz P, Geigl JB (2015). Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem, 61, 112-23.   DOI
13 Herbst A, Rahmig K, Stieber P, et al (2011). Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer. Am J Gastroenterol, 106, 1110-8.   DOI
14 Herman JG, Baylin SB (2003). Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med, 349, 2042-54.   DOI
15 Hibi K, Goto T, Mizukami H, et al (2009). MGMT gene is aberrantly methylated from the early stages of colorectal cancers. Hepatogastroenterol, 56, 1642-4.
16 Huang ZH, Li LH, Yang F, et al (2007). Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol, 13, 950-4.   DOI
17 Kim MS, Lee J, Sidransky D (2010). DNA methylation markers in colorectal cancer. Cancer Metastasis Rev, 29, 181-206.   DOI
18 Kycler W, Szarzynska B, Lozinski C, et al (2012). Analysis of O6-methylguanine-DNA methyltransferase methylation status in sporadic colon polyps. Rep Pract Oncol Radiother, 17, 13-8.   DOI
19 Lee BB, Lee EJ, Jung EH, et al (2009). Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res, 15, 6185-91.   DOI
20 Leggett BA, Hewett DG (2015). Colorectal cancer screening. Intern Med J, 45, 6-15.
21 Levin B, Lieberman DA, McFarland B, et al (2008). Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin, 58, 130-60.   DOI
22 Lo Nigro C, Wang H, McHugh A, et al (2013). Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Invest Dermatol, 133, 1278-85.   DOI
23 Lofton-Day C, Model F, Devos T, et al (2008). DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem, 54, 414-23.   DOI
24 Lu H, Huang S, Zhang X, et al (2014). DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA. Oncol Lett, 8, 1751-6.   DOI
25 Mokarram P, Kavousipour S, Sarabi MM, et al (2015). MGMT-B gene promoter hypermethylation in patients with inflammatory bowel disease - a novel finding. Asian Pac J Cancer Prev, 16, 1945-52.   DOI
26 Mokarram P, Naghibalhossaini F, Saberi Firoozi M, et al (2008). Methylenetetrahydrofolate reductase C677T genotype affects promoter methylation of tumor-specific genes in sporadic colorectal cancer through an interaction with folate/ vitamin B12 status. World J Gastroenterol, 14, 3662-71.   DOI
27 Mokarram P, Zamani M, Kavousipour S, et al (2013). Different patterns of DNA methylation of the two distinct O6- methylguanine-DNA methyltransferase (O6-MGMT) promoter regions in colorectal cancer. Mol Biol Rep, 40, 3851-7.   DOI
28 Muller HM, Oberwalder M, Fiegl H, et al (2004). Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet, 363, 1283-5.   DOI
29 Murakami T, Mitomi H, Saito T, et al (2015). Distinct WNT/ beta-catenin signaling activation in the serrated neoplasia pathway and the adenoma-carcinoma sequence of the colorectum. Mod Pathol, 28, 146-58.   DOI
30 Naghibalhossaini F, Zamani M, Mokarram P, et al (2012). Epigenetic and genetic analysis of WNT signaling pathway in sporadic colorectal cancer patients from Iran. Mol Biol Rep, 39, 6171-8.   DOI
31 Oberwalder M, Zitt M, Wontner C, et al (2008). SFRP2 methylation in fecal DNA--a marker for colorectal polyps. Int J Colorectal Dis, 23, 15-9.
32 Oh T, Kim N, Moon Y, et al (2013). Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. J Mol Diagn, 15, 498-507.   DOI
33 Okugawa Y, Grady WM, Goel A (2015). Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. Gastroenterol, 149, 1204-25.   DOI
34 Psofaki V, Kalogera C, Tzambouras N, et al (2010). Promoter methylation status of hMLH1, MGMT, and CDKN2A/p16 in colorectal adenomas. World J Gastroenterol, 16, 3553-60.   DOI
35 Salehi R, Mohammadi M, Emami MH, et al (2012). Methylation pattern of SFRP1 promoter in stool sample is a potential marker for early detection of colorectal cancer. Adv Biomed Res, 1, 87.   DOI
36 Segditsas S, Sieber OM, Rowan A, et al (2008). Promoter hypermethylation leads to decreased APC mRNA expression in familial polyposis and sporadic colorectal tumours, but does not substitute for truncating mutations. Exp Mol Pathol, 85, 201-6.   DOI
37 Segditsas S, Tomlinson I (2006). Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene, 25, 7531-7.   DOI
38 Silva AL, Dawson SN, Arends MJ, et al (2014). Boosting Wnt activity during colorectal cancer progression through selective hypermethylation of Wnt signaling antagonists. BMC Cancer, 14, 891.   DOI
39 Shah R, Jones E, Vidart V, et al (2014). Biomarkers for early detection of colorectal cancer and polyps: systematic review. Cancer Epidemiol Biomarkers Prev, 23, 1712-28.   DOI
40 Shen L, Kondo Y, Rosner GL, et al (2005). MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst, 97, 1330-8.   DOI
41 Stoffel EM, Boland CR (2015). Genetics and Genetic Testing in Hereditary Colorectal Cancer. Gastroenterol, 149, 1191-203.   DOI
42 Stracci F, Zorzi M, Grazzini G (2014). Colorectal Cancer Screening: Tests, Strategies, and Perspectives. Frontiers Public Health, 2, 210.
43 Summers T, Langan RC, Nissan A, et al (2013). Serum-based DNA methylation biomarkers in colorectal cancer: potential for screening and early detection. J Cancer, 4, 210-6.   DOI
44 Takane K, Midorikawa Y, Yagi K, et al (2014). Aberrant promoter methylation of PPP1R3C and EFHD1 in plasma of colorectal cancer patients. Cancer Med, 3, 1235-45.   DOI
45 Takeda M, Nagasaka T, Dong-Sheng S, et al (2011). Expansion of CpG methylation in the SFRP2 promoter region during colorectal tumorigenesis. Acta Med Okayama, 65, 169-77.
46 Tang D, Liu J, Wang DR, et al (2011). Diagnostic and prognostic value of the methylation status of secreted frizzled-related protein 2 in colorectal cancer. Clin Invest Med, 34, 88-95.   DOI
47 Tanzer M, Balluff B, Distler J, et al (2010). Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One, 5, 9061.   DOI
48 Wang D-R, Tang D (2008). Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol, 14, 524-31.   DOI
49 van Bemmel D, Lenz P, Liao LM, et al (2012). Correlation of LINE-1 methylation levels in patient-matched buffy coat, serum, buccal cell, and bladder tumor tissue DNA samples. Cancer Epidemiol Biomarkers Prev, 21, 1143-8.   DOI
50 Voorham QJ, Janssen J, Tijssen M, et al (2013). Promoter methylation of Wnt-antagonists in polypoid and nonpolypoid colorectal adenomas. BMC Cancer, 13, 603.   DOI
51 Wang X, Kuang YY, Hu XT (2014). Advances in epigenetic biomarker research in colorectal cancer. World J Gastroenterol, 20, 4276-87.   DOI
52 Wang Z, Jiang W, Wang Y, et al (2015). promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma. Biomed Rep, 3, 543-8.   DOI
53 Whitehall VL, Walsh MD, Young J, et al (2001). Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res, 61, 827-30.
54 Yi JM, Dhir M, Guzzetta AA, et al (2012). DNA methylation biomarker candidates for early detection of colon cancer. Tumour Biol, 33, 363-72.   DOI
55 Ying Y, Tao Q (2009). Epigenetic disruption of the WNT/betacatenin signaling pathway in human cancers. Epigenetics, 4, 307-12.   DOI
56 Zhang W, Bauer M, Croner RS, et al (2007). DNA stool test for colorectal cancer: hypermethylation of the secreted frizzledrelated protein-1 gene. Dis Colon Rectum, 50, 1618-26.   DOI
57 Zou H, Harrington JJ, Shire AM, et al (2007). Highly methylated genes in colorectal neoplasia: implications for screening. Cancer Epidemiol Biomarkers Prev, 16, 2686-96.   DOI
58 Zhang X, Song YF, Lu HN, et al (2015). Combined detection of plasma GATA5 and SFRP2 methylation is a valid noninvasive biomarker for colorectal cancer and adenomas. World J Gastroenterol, 21, 2629-37.   DOI